With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1233318-23-4,Methyl 2-(quinoxalin-6-yl)acetate,as a common compound, the synthetic route is as follows.
To dimethyl carbonate (30 mL) cooled at 0 was added potassium tert-butanolate (3.8 g, 34.12 mmol) in portions. The resultant mixture was stirred at 0 for 1 hour. Methyl 2- (quinoxalin-6-yl) acetate (2.3 g, 11.37 mmol) was added. The resultant mixture was slowly warmed up to room temperature and stirred for 1 hour. The reaction mixture was heated to 90 and stirred for 1.5 hours. After cooling to room temperature, the mixture was diluted with EtOAc (150 mL) , washed with saturated NH4Cl (80 mL) and brine (50 mL) , dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column (petroleum ether/ethyl acetate3: 1) to obtain dimethyl 2- (quinoxalin-6-yl) malonate (2.0 g) as a yellow solid. 1H NMR (CHLOROFORM-d) : delta 8.89 (s, 2H) , 8.10 -8.19 (m, 2H) , 7.91 (dd, J 8.7, 2.0 Hz, 1H) , 4.95 (s, 1H) , 3.82 (s, 6H) . LC-MS: m/z 261.1 (M+H) +., 1233318-23-4
As the paragraph descriping shows that 1233318-23-4 is playing an increasingly important role.
Reference£º
Patent; AGIOS PHARMACEUTICALS, INC.; TRAVINS, Jeremy, M.; KONTEATIS, Zenon, D.; SUI, Zhihua; YE, Zhixiong; (199 pag.)WO2018/39972; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider